ES2031462T3 - Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima. - Google Patents

Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.

Info

Publication number
ES2031462T3
ES2031462T3 ES198787104071T ES87104071T ES2031462T3 ES 2031462 T3 ES2031462 T3 ES 2031462T3 ES 198787104071 T ES198787104071 T ES 198787104071T ES 87104071 T ES87104071 T ES 87104071T ES 2031462 T3 ES2031462 T3 ES 2031462T3
Authority
ES
Spain
Prior art keywords
arabinofuranosilcitosina
produce
procedure
sterarilfosfato
monosodico
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787104071T
Other languages
English (en)
Inventor
Takashi Terada
Minoru Aoki
Hiroshi Ohtaki
Manami Morozumi
Mitsuharu Shiozaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Kayaku Co Ltd
Yamasa Shoyu KK
Original Assignee
Nippon Kayaku Co Ltd
Yamasa Shoyu KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP61063963A external-priority patent/JPS62221696A/ja
Priority claimed from JP61114680A external-priority patent/JPS62273993A/ja
Application filed by Nippon Kayaku Co Ltd, Yamasa Shoyu KK filed Critical Nippon Kayaku Co Ltd
Application granted granted Critical
Publication of ES2031462T3 publication Critical patent/ES2031462T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE DESCRIBE UN NUEVO PROCEDIMIENTO PARA PRODUCIR LA SAL MONOSODICA DEL 1-BETA-D-ARABINOFURANOSILCITOSINA-5''-ESTEARILFOSFATO, QUE SE ANUNCIA COMO AGENTE ANTITUMORAL Y DE SU MONOHIDRATO A PARTIR DE DICHA SAL MONOSODICA. TAMBIEN SE DESCRIBE UNA COMPOSICION FARMACEUTICA QUE CONTIENE EL MENCIONADO MONOHIDRATO Y SU EMPLEO COMO MEDICAMENTO, EN ESPECIAL EN EL TRATAMIENTO DE TUMORES.
ES198787104071T 1986-03-24 1987-03-19 Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima. Expired - Lifetime ES2031462T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61063963A JPS62221696A (ja) 1986-03-24 1986-03-24 １−β−Ｄ−アラビノフラノシルシトシン−５′−ステアリルりん酸モノナトリウム塩・１水和物
JP61114680A JPS62273993A (ja) 1986-05-21 1986-05-21 １−β−Ｄ−アラビノフラノシルシトシン−５′−ステアリルりん酸ナトリウム塩の新規製造法

Publications (1)

Publication Number Publication Date
ES2031462T3 true ES2031462T3 (es) 1992-12-16

Family

ID=26405089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787104071T Expired - Lifetime ES2031462T3 (es) 1986-03-24 1987-03-19 Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.

Country Status (8)

Country Link
US (2) US4812560A (es)
EP (1) EP0239015B1 (es)
KR (1) KR910008801B1 (es)
AU (1) AU592165B2 (es)
CA (1) CA1270820A (es)
DE (1) DE3773716D1 (es)
ES (1) ES2031462T3 (es)
HU (1) HU196429B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239015B1 (en) * 1986-03-24 1991-10-16 Nippon Kayaku Kabushiki Kaisha Process for producing 1-beta-d-arabinofuranosylcytosine-5'-stearylphosphate monosodium salt and monohydrate thereof, and pharmaceutical composition containing the latter
DE69330392T2 (de) * 1992-04-03 2001-11-08 Nippon Kayaku K.K., Tokio/Tokyo Cytarabine Ocfosfate enthaltende harte Kapsel
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
PE20011065A1 (es) 2000-02-01 2001-11-21 Procter & Gamble Proceso para fabricar bisfosfonatos geminales
KR20040078123A (ko) 2002-01-14 2004-09-08 노파르티스 아게 에포틸론 및 대사길항물질을 포함하는 조합물
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5516440B2 (es) * 1973-11-08 1980-05-01
JPS5289681A (en) * 1976-01-22 1977-07-27 Yamasa Shoyu Co Ltd Preparation of aracytidine -5# phosphoric acid ester derivatives
JPS552601A (en) * 1978-06-20 1980-01-10 Yamasa Shoyu Co Ltd Anti-tumor agent for non-injection use
JPS55129299A (en) * 1980-03-14 1980-10-06 Yamasa Shoyu Co Ltd 1-beta-d-arabinofuranosyl-cytosine-5'-phosphoric alkyl ester
EP0239015B1 (en) * 1986-03-24 1991-10-16 Nippon Kayaku Kabushiki Kaisha Process for producing 1-beta-d-arabinofuranosylcytosine-5'-stearylphosphate monosodium salt and monohydrate thereof, and pharmaceutical composition containing the latter
JP3236058B2 (ja) * 1992-04-14 2001-12-04 富士通テン株式会社 オーディオ再生装置

Also Published As

Publication number Publication date
US5049663A (en) 1991-09-17
HU196429B (en) 1988-11-28
US4812560A (en) 1989-03-14
AU592165B2 (en) 1990-01-04
AU7047587A (en) 1987-10-01
HUT44270A (en) 1988-02-29
EP0239015A3 (en) 1989-03-22
KR910008801B1 (ko) 1991-10-21
EP0239015B1 (en) 1991-10-16
EP0239015A2 (en) 1987-09-30
KR870008909A (ko) 1987-10-22
DE3773716D1 (de) 1991-11-21
CA1270820A (en) 1990-06-26

Similar Documents

Publication Publication Date Title
AU7023987A (en) Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
MY125414A (en) Aminopropylphosphinic acids
EP0151989A3 (en) Means for the treatment of cardiac diseases
ES2178048T3 (es) Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
ES8102141A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
AR001073A1 (es) Benzoilguanidinas basicamente sustituidas procedimientos para su preparación su empleo como medicamento o agente de diagnostico asi como medicamento que las contiene
ES2149279T3 (es) Sistema terapeutico para el tratamiento de la psoriasis.
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
WO1987000432A3 (en) Use of melatonin or related compounds for the treatment of psoriasis
NO891220D0 (no) Middel som inneholder salicylsyre for behandling av lepidose.
ITMI921556A1 (it) Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ATE5073T1 (de) 5-amino-tetrazol-derivate von retinsaeuren, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 239015

Country of ref document: ES